FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2059503876> ?p ?o ?g. }

• W2059503876 endingPage "233" @default.
• W2059503876 startingPage "224" @default.
• W2059503876 abstract "Aim: Alogliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, and voglibose, an alpha-glucosidase inhibitor, have different but complementary mechanisms of action on glucagon-like peptide-1 (GLP-1) regulation and glucose-lowering effects. The present study evaluated the chronic effects of combination treatment with alogliptin and voglibose in prediabetic db/db mice. Methods: Alogliptin (0.03%) and voglibose (0.001%) alone or in combination were administered in the diet to prediabetic db/db mice. Results: After 3 weeks, voglibose treatment increased GLP-1 secretion (voglibose alone, 1.6-fold; alogliptin plus voglibose, 1.5-fold), while it decreased plasma glucose-dependent insulinotropic polypeptide (GIP) (voglibose alone, −30%; alogliptin plus voglibose, −29%). Alogliptin, voglibose and combination treatment decreased plasma DPP-4 activity by 72, 15 and additively by 80%, respectively, and increased plasma active GLP-1 levels by 4.5-, 1.8- and synergistically by 9.1-fold respectively. Combination treatment increased plasma insulin by 3.6-fold (alogliptin alone, 1.3-fold; voglibose alone, 1.8-fold), decreased plasma glucagon by 30% (alogliptin alone, 11%; voglibose alone, 8%), and prevented the development of diabetes, much more effectively than either agent alone. After 4 weeks, alogliptin, voglibose and combination treatment increased pancreatic insulin content by 1.6-, 3.4- and synergistically by 8.5-fold respectively. Furthermore, combination treatment resulted in an increased expression of insulin, pancreatic and duodenal homeobox 1 (PDX1) and glucose transporter 2 (GLUT2), and maintenance of normal beta/alpha-cell distribution in the pancreatic islet. Conclusions: Chronic treatment with alogliptin in combination with voglibose concurrently increased active GLP-1 circulation, increased insulin secretion, decreased glucagon secretion, prevented the onset of the disease, and preserved pancreatic beta-cells and islet structure in prediabetic db/db mice." @default.
• W2059503876 created "2016-06-24" @default.
• W2059503876 creator A5007512358 @default.
• W2059503876 creator A5060762563 @default.
• W2059503876 creator A5090713682 @default.
• W2059503876 date "2010-03-01" @default.
• W2059503876 modified "2023-10-18" @default.
• W2059503876 title "Combination treatment with alogliptin and voglibose increases active GLP-1 circulation, prevents the development of diabetes and preserves pancreatic beta-cells in prediabetic<i>db/db</i>mice" @default.
• W2059503876 cites W143876065 @default.
• W2059503876 cites W1584240097 @default.
• W2059503876 cites W1824143413 @default.
• W2059503876 cites W1842412649 @default.
• W2059503876 cites W1961977850 @default.
• W2059503876 cites W1973489602 @default.
• W2059503876 cites W1976026431 @default.
• W2059503876 cites W1986044732 @default.
• W2059503876 cites W1997505976 @default.
• W2059503876 cites W2001031720 @default.
• W2059503876 cites W2008978729 @default.
• W2059503876 cites W2013361913 @default.
• W2059503876 cites W2017518223 @default.
• W2059503876 cites W2027593203 @default.
• W2059503876 cites W2031428711 @default.
• W2059503876 cites W2033597135 @default.
• W2059503876 cites W2034419419 @default.
• W2059503876 cites W2037741963 @default.
• W2059503876 cites W2040123871 @default.
• W2059503876 cites W2042537754 @default.
• W2059503876 cites W2045326048 @default.
• W2059503876 cites W2046611107 @default.
• W2059503876 cites W2048371631 @default.
• W2059503876 cites W2049067099 @default.
• W2059503876 cites W2055328904 @default.
• W2059503876 cites W2062614567 @default.
• W2059503876 cites W2064780710 @default.
• W2059503876 cites W2074835704 @default.
• W2059503876 cites W2082767535 @default.
• W2059503876 cites W2084403835 @default.
• W2059503876 cites W2098933436 @default.
• W2059503876 cites W2102392334 @default.
• W2059503876 cites W2104162165 @default.
• W2059503876 cites W2106154942 @default.
• W2059503876 cites W2106984011 @default.
• W2059503876 cites W2131676185 @default.
• W2059503876 cites W2135854640 @default.
• W2059503876 cites W2149795396 @default.
• W2059503876 cites W2156471774 @default.
• W2059503876 cites W2159859567 @default.
• W2059503876 cites W2166312550 @default.
• W2059503876 doi "https://doi.org/10.1111/j.1463-1326.2009.01156.x" @default.
• W2059503876 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20151999" @default.
• W2059503876 hasPublicationYear "2010" @default.
• W2059503876 type Work @default.
• W2059503876 sameAs 2059503876 @default.
• W2059503876 citedByCount "49" @default.
• W2059503876 countsByYear W20595038762012 @default.
• W2059503876 countsByYear W20595038762013 @default.
• W2059503876 countsByYear W20595038762014 @default.
• W2059503876 countsByYear W20595038762015 @default.
• W2059503876 countsByYear W20595038762016 @default.
• W2059503876 countsByYear W20595038762017 @default.
• W2059503876 countsByYear W20595038762018 @default.
• W2059503876 countsByYear W20595038762019 @default.
• W2059503876 countsByYear W20595038762023 @default.
• W2059503876 crossrefType "journal-article" @default.
• W2059503876 hasAuthorship W2059503876A5007512358 @default.
• W2059503876 hasAuthorship W2059503876A5060762563 @default.
• W2059503876 hasAuthorship W2059503876A5090713682 @default.
• W2059503876 hasConcept C126322002 @default.
• W2059503876 hasConcept C134018914 @default.
• W2059503876 hasConcept C156490143 @default.
• W2059503876 hasConcept C165220095 @default.
• W2059503876 hasConcept C2776828364 @default.
• W2059503876 hasConcept C2777180221 @default.
• W2059503876 hasConcept C2778763485 @default.
• W2059503876 hasConcept C2778881409 @default.
• W2059503876 hasConcept C2779306644 @default.
• W2059503876 hasConcept C2780012697 @default.
• W2059503876 hasConcept C555293320 @default.
• W2059503876 hasConcept C71924100 @default.
• W2059503876 hasConcept C98274493 @default.
• W2059503876 hasConceptScore W2059503876C126322002 @default.
• W2059503876 hasConceptScore W2059503876C134018914 @default.
• W2059503876 hasConceptScore W2059503876C156490143 @default.
• W2059503876 hasConceptScore W2059503876C165220095 @default.
• W2059503876 hasConceptScore W2059503876C2776828364 @default.
• W2059503876 hasConceptScore W2059503876C2777180221 @default.
• W2059503876 hasConceptScore W2059503876C2778763485 @default.
• W2059503876 hasConceptScore W2059503876C2778881409 @default.
• W2059503876 hasConceptScore W2059503876C2779306644 @default.
• W2059503876 hasConceptScore W2059503876C2780012697 @default.
• W2059503876 hasConceptScore W2059503876C555293320 @default.
• W2059503876 hasConceptScore W2059503876C71924100 @default.
• W2059503876 hasConceptScore W2059503876C98274493 @default.
• W2059503876 hasIssue "3" @default.
• W2059503876 hasLocation W20595038761 @default.
• W2059503876 hasLocation W20595038762 @default.
• W2059503876 hasOpenAccess W2059503876 @default.

• next